[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]In collaboration with Acceleron Pharma. [d]In collaboration with Agios Pharmaceuticals, Inc. [e]In collaboration with Epizyme, Inc.

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, and VIDAZA® are registered trademarks of Celgene Corporation.

© 2015 Celgene Corporation 08/15

	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post-Approval Research[b]
Lymphoma						
REVLIMID® (lenalidomide)	Mantle cell lymphoma: Relapsed/refractory (US)					
	Mantle cell lymphoma: Relapsed/refractory (EU)					
	Diffuse large B-cell: Maintenance					
	Diffuse large B-cell (ABC-subtype): First-line					
	Indolent lymphoma: Relapsed/refractory					
	Follicular lymphoma: First-line					
	Adult T-cell leukemia-lymphoma (Japan)					
ISTODAX® (romidepsin) for injection	Cutaneous T-cell lymphoma (US)[c]					
	Peripheral T-cell lymphoma: Relapsed/refractory (US)[c]					
	Peripheral T-cell lymphoma: Relapsed/refractory (Japan)					
	Peripheral T-cell lymphoma: First-line					
PPM™ Pleiotropic Pathway Modifier: CC-122	Diffuse large B-cell					
	Indolent lymphoma: Relapsed/refractory					
CC-486						
Chronic Lymphocytic Leukemia (CLL)						
REVLIMID® (lenalidomide)	Maintenance: Second-line					
PPM™ Pleiotropic Pathway Modifier: CC-122						
Beta Thalassemia						
luspatercept (ACE-536)[d]	Beta-thalassemia					

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Filing for regulatory approval based on pivotal phase II data.
[d]In collaboration with Acceleron Pharma.

REVLIMID® and ISTODAX® are registered trademarks of Celgene Corporation. PPM™ is a trademark of Celgene Corporation.

© 2015 Celgene Corporation 08/15



[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd.
[d]In collaboration with Agios Pharmaceuticals, Inc. agios

ABRAXANE® is a registered trademark of Celgene Corporation. PPM™ is a trademark of Celgene Corporation.

© 2015 Celgene Corporation 08/15

	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post-Approval Research[b]
Inflammation & Immunology						
OTEZLA® (apremilast)	Psoriatic arthritis					
	Psoriasis					
	Psoriatic arthritis/Psoriasis (Japan)					
	Ankylosing spondylitis					
	Behçet's disease					
	Atopic dermatitis					
	Ulcerative colitis					
GED-0301	Crohn's disease					
	Ulcerative colitis					
ozanimod	Relapsing multiple sclerosis					
	Ulcerative colitis					
	Crohn's disease					
RPC-4046[c]	Eosinophilic esophagitis					
sotatercept (ACE-011)[d]	Renal anemia with metabolic bone disease					
CC-220	Systemic lupus erythematosus					
CC-90001	Fibrosis					
Cellular Therapies						
BIOVANCE®[e,f] (human amniotic membrane allograft)	Wound management					
Extracellular matrix[g]	Wound management					
PDA-002	Peripheral artery disease/Diabetic foot ulcers					
PDA-001	Crohn's disease					

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Under co-development option with AbbVie.
[d]In collaboration with Acceleron Pharma. [e]Regulated under Section 361 of the Public Health Service Act. [f]Processed for Alliqua Biomedical by Celgene Cellular Therapeutics.
[g]Dermal Repair Scaffold (DRS) a 510(k) device and Connective Tissue Matrix (CTM) regulated under section 361 of the Public Health Service Act, both manufactured for Alliqua Biomedical by Celgene Cellular Therapeutics.

OTEZLA® and BIOVANCE® are registered trademarks of Celgene Corporation.

© 2015 Celgene Corporation 08/15